
Trevena grabs $35M to fund trials of heart-failure drug
Trevena Inc. has landed a sizable $35 million Series B round that it hopes will push its lead heart-failure drug through Phase 2 clinical trials. The funding was led by venture heavyweights and existing investors Polaris Venture Partners and New Enterprise Associates. Other previous investors — Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company […]